Research programme: infectious diseases vaccines - Crucell/Wyeth
Latest Information Update: 16 Jun 2011
At a glance
- Originator Crucell; Wyeth
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Infections
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 13 Mar 2008 Preclinical trials in Infections in Switzerland (Parenteral)